Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry describes a non-coding RNA whose sequence is antisense to the RND3 gene. Natural antisense transcripts (NATs) like this can regulate expression of adjacent or overlapping genes through various mechanisms, including modulation of chromatin state, transcriptional interference, and masking of miRNA-binding sites[1][2][3][4][5]. However, this particular transcript does not have a well-defined protein-coding function or established direct link to disease or drug targeting. Its biological activity, if any, would be regulatory in nature and dependent on effects on RND3 gene expression or chromatin environment. The attribution "novel transcript" suggests it is computationally or experimentally identified but not necessarily functionally characterized. The provided Ensembl gene ID does not map to a standard, stable annotated gene and may indicate provisional or outdated nomenclature. In summary, "novel transcript, antisense to RND3" is most accurately described as a non-coding antisense RNA of unclear clinical or experimental significance, not a targetable receptor or enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RND3.